-+ 0.00%
-+ 0.00%
-+ 0.00%

GALMED ANNOUNCES A COLLABORATION AGREEMENT WITH TEL AVIV UNIVERSITY TO EVALUATE ITS SCD1 INHIBITOR, ARAMCHOL, AS A TARGETED THERAPY FOR METASTATIC BRAIN CANCERS

Reuters·04/14/2026 11:30:00

Please log in to view news